Child malignancy survival: an interview with Prof Kathy Pritchard-Jones.

Child malignancy survival: an interview with Prof Kathy Pritchard-Jones, University University London By April Cashin-Garbutt Interview conducted, BA Hons Make sure you can you give a brief history of childhood cancer survival rates over the past 50 years? Back in the early 1960s, just before chemotherapy began to be used, no more than 30 percent of children survived cancer. That was because they had cancers that were amenable to medical procedures mainly . So, with the growth of chemotherapy and the understanding of how to use it, we've seen a steady improvement from 30 percent survival rates back the 1960s to around 80 percent of children expected to survive childhood malignancy in the 2000s.

To fast monitor the most relevant and new medicines for childhood cancers will demand a renewed concentrate on the potential role of adult cancer drugs in children and also newer methods and scientific trial design that aim to more quickly predict the perfect dose. In recent years, it’s been industry which has driven the clinical trials in children to meet up regulatory requirements rather than the paediatric oncology expert community who understand the medical unmet needs of children and teenagers with cancer, compose the authors. This is necessary as these illnesses are rare already, and dividing patients into increasingly smaller biological subgroups might amount to just a couple of trial participants a season in each country. This therapeutic alliance will make sure that efforts are centered on the unmet medical needs of young people with cancer.